Holen Sie sich die Stockscreener-App
25.85
0.19%
0.05
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt PFE?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$25.80
Offen:
$25.835
24-Stunden-Volumen:
51.03M
Relative Volume:
0.76
Marktkapitalisierung:
$146.98B
Einnahmen:
$62.79B
Nettoeinkommen (Verlust:
$9.84B
KGV:
15.07
EPS:
1.7156
Netto-Cashflow:
$10.38B
1W Leistung:
-0.69%
1M Leistung:
-0.08%
6M Leistung:
+4.07%
1J Leistung:
+1.89%
1-Tages-Spanne:
$25.72
$26.04
1-Wochen-Bereich:
$25.13
$26.19
52-Wochen-Spanne:
$20.91
$27.69
Pfizer Inc Stock (PFE) Company Profile
Firmenname
Pfizer Inc
Sektor
Telefon
(212) 733-2323
Adresse
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Vergleichen Sie PFE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
25.85 | 146.69B | 62.79B | 9.84B | 10.38B | 1.7156 |
|
LLY
Lilly Eli Co
|
1,027.51 | 903.41B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
211.58 | 505.98B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
223.32 | 395.86B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
132.57 | 253.97B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
100.30 | 245.75B | 63.90B | 19.05B | 13.05B | 7.5596 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-02 | Fortgesetzt | Citigroup | Neutral |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-25 | Fortgesetzt | Citigroup | Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Herabstufung | Argus | Buy → Hold |
| 2024-02-23 | Eingeleitet | Guggenheim | Buy |
| 2024-01-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-10-16 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-17 | Bestätigt | JP Morgan | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-06-29 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Herabstufung | UBS | Buy → Neutral |
| 2023-01-17 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-13 | Hochstufung | Goldman | Neutral → Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-20 | Bestätigt | Cowen | Outperform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-13 | Hochstufung | UBS | Neutral → Buy |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-05-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-12-16 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Fortgesetzt | Goldman | Neutral |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-10-12 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-16 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-27 | Hochstufung | Standpoint Research | Hold → Buy |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-07-30 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-02-20 | Fortgesetzt | Citigroup | Neutral |
| 2019-01-31 | Hochstufung | Argus | Hold → Buy |
| 2019-01-31 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Herabstufung | UBS | Buy → Neutral |
| 2018-12-11 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
Alle ansehen
Pfizer Inc Aktie (PFE) Neueste Nachrichten
Forget Teladoc and Buy This Healthcare Stock Instead - Yahoo Finance
Bellevue Group AG Reduces Holdings in Pfizer Inc. $PFE - MarketBeat
Banque Transatlantique SA Lowers Stake in Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. $PFE Shares Purchased by Adage Capital Partners GP L.L.C. - MarketBeat
Pfizer (PFE) Stock After Hours on Dec. 12, 2025: Dividend Update, FDA “Black Box” Headline, Analyst Forecasts — What to Know Before the Next Market Open - ts2.tech
Pfizer (PFE) Stock After Hours on Dec. 12, 2025: Dividend Update, FDA Vaccine Warning Headlines, and What to Watch Before the Next Market Open - ts2.tech
Pfizer Inc. Declares First-Quarter 2026 Dividend, Payable on March 6, 2026 - marketscreener.com
Pfizer declares $0.43 quarterly dividend payable in March 2026 - Investing.com
Pfizer declares $0.43 quarterly dividend payable in March 2026 By Investing.com - Investing.com Canada
Pfizer Declares First-Quarter 2026 Dividend - Business Wire
Pfizer Is Still Struggling to Replace Its COVID Revenue. Here's What We Could See From the Pharmaceutical Giant in 2026. - The Globe and Mail
The Best Turnaround Stock to Invest $1,000 in Right Now - Finviz
Is Pfizer Shifting From Defensive Stock To Value Opportunity After Post Pandemic Restructuring? - simplywall.st
Health Rounds: Pfizer drug delays progression of advanced breast cancer in trial - Reuters
Morgan Stanley Adjusts Price Target on Pfizer to $28 From $32, Maintains Equalweight Rating - marketscreener.com
Elevance Health Adds Former Pfizer GC To Its Board - Law360
Pfizer (PFE) Stock Outlook After the November 21 FDA Win: Obesity Deals, Cost Cuts and a 6.7% Dividend Yield - ts2.tech
Ex-Pfizer executive joins Elevance’s board as insurer pursues pharmacy experience - Healthcare Dive
Pfizer plans job cuts in Switzerland to reduce expenses - Yahoo Finance
Down 50%, should you buy the dip on Pfizer? - MSN
Pfizer Inc. (PFE) Announces Results from Phase 3 BASIS Study - Finviz
IDEAYA Biosciences Completes Targeted Full Enrollment in Trial of Darovasertib With Pfizer's Crizotinib - marketscreener.com
Will Obesity Bet and TUKYSA Data Shift Pfizer’s (PFE) Post-COVID Growth Narrative? - simplywall.st
3SBio Sells Shares, Divests Subsidiary To Boost Capital - Benzinga
How the Narrative Surrounding Pfizer Is Changing After Obesity Deals and Sector Rerating - Yahoo Finance
Pfizer Plans Workforce Reduction in Switzerland - marketscreener.com
Pfizer Could Claim Tukysa First-Line HER2+ Metastatic Breast Cancer Indication - Citeline News & Insights
Pfizer (PFE) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
Pfizer to cut hundreds of jobs in Switzerland by year-end - Investing.com India
Pfizer stock gets Outperform rating from BMO as tucatinib shows promise - Investing.com
Former Pfizer physician challenges RIF, OWBPA disclosures in court - HRD America
Pfizer Plans to Cut 200+ Employees in Switzerland: Wire - AASTOCKS.com
Pfizer is shedding hundreds of jobs in Switzerland (PFE:NYSE) - Seeking Alpha
Pfizer to cut over 200 jobs in Switzerland to reduce costs, Bloomberg News reports - Reuters
Pfizer Inc. (PFE) announces results from the phase 3 BASIS study evaluating HYMPAVZI - MSN
Pfizer Inc. (PFE) Announces Results from the Phase 3 BASIS Study Evaluating HYMPAVZI - Finviz
Pfizer to cut hundreds of jobs in Switzerland to reduce costs, Bloomberg News reports - marketscreener.com
Pfizer is cutting hundreds of jobs in Switzerland to lower costsBloomberg News - marketscreener.com
Pfizer Is Cutting Hundreds of Jobs in Switzerland to Lower Costs - Bloomberg.com
Expression Therapeutics Taps Former Pfizer, Novartis Exec as CEO - Contract Pharma
Pfizer’s tucatinib reduces disease progression risk in HER2+ breast cancer By Investing.com - Investing.com Australia
Pfizer Says Metatstatic Breast Cancer Treatment Extends Median Progression-Free Survival - marketscreener.com
PFIZER INC : JP Morgan remains Neutral - marketscreener.com
Pfizer’s tucatinib reduces disease progression risk in HER2+ breast cancer - Investing.com
Pfizer announces results from phase 3 HER2CLIMB-05 trial of Tukysa - marketscreener.com
Pfizer’s Tukysa Slows Breast Cancer When Added to First-Line Care - Bloomberg.com
Fosun's Yao Pharma, Pfizer sign exclusive collaboration dealVietnam Investment Review - Vietnam Investment Review - VIR
Intact Investment Management Inc. Has $16.21 Million Stake in Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. $PFE Shares Sold by Lombard Odier Asset Management Switzerland SA - MarketBeat
HSBC Adjusts Price Target on Pfizer to $29 From $28, Maintains Buy Rating - marketscreener.com
China's Fosun Pharma unit strikes US$2.1 billion obesity drug deal with Pfizer - Yahoo Finance
Finanzdaten der Pfizer Inc-Aktie (PFE)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.28%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):